IONIS PHARMACEUTICALS INC
zilganersen
Alexander disease
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews zilganersen for Alexander disease around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 15h ago
“Zilganersen is currently under Priority Review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) action date of September 22, 2026.”